OPTIMA Trial Shows 90.4% 5-Year Survival Without Chemo in Some Early Breast Cancer
Updated
Updated · DocWire News · May 29
OPTIMA Trial Shows 90.4% 5-Year Survival Without Chemo in Some Early Breast Cancer
2 articles · Updated · DocWire News · May 29
4,429 patients in the OPTIMA trial showed a Prosigna-guided strategy could omit chemotherapy for some high-risk ER-positive/HER2-negative early breast cancer patients without sacrificing 5-year invasive breast cancer-free survival.
5-year IBCFS reached 90.4% in the test-directed arm versus 91.5% with standard chemotherapy plus endocrine therapy, meeting the trial’s predefined 3% non-inferiority margin.
Patients with Prosigna risk-of-recurrence scores above 60 received chemotherapy, while those scoring 60 or below received endocrine therapy alone; no outcome differences emerged across menopausal or nodal subgroups.
280 IBCFS events were recorded after a median 3.9 years of follow-up, with 66% of events being distant recurrences.
The ASCO-presented results support using gene-expression profiling to reduce overtreatment and spare selected patients chemotherapy’s short- and long-term toxicities.
A new test spares thousands from chemo, but is a 1% higher cancer recurrence risk an acceptable trade-off?
As genomic tests make cancer care more precise, who ultimately pays for this personalized medicine revolution?
OPTIMA Trial Results: Prosigna Genomic Test Enables Chemotherapy Omission for Many Breast Cancer Patients
Overview
The OPTIMA trial is set to revolutionize breast cancer treatment by showing that many women can safely avoid chemotherapy, sparing them from its severe side effects. This breakthrough is possible because genomic testing with Prosigna provides a precise assessment of each patient’s risk, allowing doctors to tailor treatment plans. Patients with a Prosigna risk of recurrence score of 60 or less may not need chemotherapy, marking a major step toward more individualized and less aggressive care. By leveraging these genomic insights, the trial supports safer, more effective, and patient-centered breast cancer management.